Tag: GlobeNewswire

MONACO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Costamare Bulkers Holdings Limited (the “Company”) (NYSE: CMDB), an international owner and operator of dry bulk vessels, announced the election of one Class I director at the Company’s virtual annual meeting of stockholders held today.

The elected Class I director is Dimitrios Sofianopoulos, who was elected to hold office for a term ending at the annual meeting of stockholders in 2029 and until his successor has been duly elected and qualified.

Stockholders also ratified the appointment of Ernst & Young (Hellas) Certified Auditors Accountants S.A. as the Company’s independent auditors for the fiscal year ending December 31, 2026.

About Costamare Bulkers Holdings Limited

Costamare Bulkers Holdings Limited is an international owner and operator of dry bulk vessels. Costamare Bulkers’ owned dry bulk fleet consists of 30 vessels (including one vessel we have agreed to sell) with a total carrying capacity of approximately 2,665,000 DWT. Costamare Bulkers also owns a dry bulk operating platform (CBI) which charters in/out dry bulk vessels, enters into contracts of affreightment, forward freight agreements and may also utilize hedging solutions. Costamare Bulkers’ common stock trades on the New York Stock Exchange under the symbol “CMDB”.

Forward-Looking Statements

This press release contains “forward-looking statements”. In some cases, you can identify these statements by forward-looking words such as “believe”, “intend”, “anticipate”, “estimate”, “project”, “forecast”, “plan”, “potential”, “may”, “should”, “could”, “expect” and similar expressions. You should not place undue reliance on these statements. These statements are not historical facts but instead represent only the Company’s beliefs regarding future results, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Although the Company believes that its expectations stated in this press release are based on reasonable assumptions, it is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in the Company’s Annual Report on Form 20-F (File No. 001-42581).
All forward-looking statements reflect management’s current views with respect to certain future events, and the Company expressly disclaims any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in the Company’s views or expectations, or otherwise.

Company Contacts:
Gregory Zikos – Chief Executive Officer
Dimitris Pagratis – Chief Financial Officer
Konstantinos Tsakalidis – Business Development

Costamare Bulkers Holdings Limited, Monaco
Tel: (+377) 92 00 1745
Email: ir@costamarebulkers.com

Data-first workflow lets lenders review credit insights before purchasing scores

CHICAGO, Oct. 08, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today launched TransUnion First Look Functionality for Mortgage, enabling mortgage lenders to review credit insights before purchasing scores. The innovation follows TransUnion’s recent extension of 99-cent VantageScore® 4.0 mortgage pricing through 2028, with no charge when lenders pull it alongside a FICO® Score. Combined, these advancements help lenders improve origination efficiency, reduce costs and align credit spending more closely with loan progression.

Traditional mortgage workflows often require lenders to purchase credit scores early, even when the underlying credit data often provides the necessary information to determine whether a loan should advance, follow a streamlined path, or be removed from consideration. Whether using a soft-pull solution such as TruVision® Early Access Soft Check or a traditional hard-pull workflow, lenders frequently need multiple scores throughout the origination process. Purchasing those scores before they are needed can lead to unnecessary fallout costs for lenders.

“Mortgage lenders face sustained pressure to control costs and operate more efficiently without compromising underwriting decisions. TransUnion First Look Functionality for Mortgage allows lenders to start with credit report insights and add additional score-based decisioning only when needed,” said Satyan Merchant, senior vice president and mortgage business leader at TransUnion. “First Look Functionality provides insight earlier in the lending journey, directs resources toward the most promising opportunities and creates a more efficient path from application to closing.” 

With TransUnion First Look Functionality for Mortgage, lenders can evaluate early-stage risk by purchasing either a credit report alone or a credit report with the score of their choice, then request additional score(s) only when needed. Lenders do not incur the cost of a second credit report when adding additional score(s) when all eligibility and matching conditions are met. Additionally, TransUnion First Look Functionality for Mortgage is compatible with government-sponsored enterprises (GSEs) and the Federal Housing Administration (FHA) automated underwriting workflows, enabling seamless implementation without requiring changes to existing selling guidelines or policies.

Available for both soft- and hard-pull workflows and through mortgage resellers, lenders can capture efficiencies without redesigning existing processes. For instance, through Early Access Soft Check, lenders can assess borrower eligibility earlier by using the TransUnion credit report along with VantageScore 4.0, in addition to indicators on the credit report such as bankruptcy risk, streamlined-program eligibility and other underwriting considerations, before another score is needed.

Trended credit data and optional solutions like TruVision Alternative Credit Attributes and TruVision Income and Employment Verification can also provide additional insight in both soft and hard-pull workflows while helping reduce unnecessary credit expenses and maintain decision quality.
  
Learn more about TransUnion First Look Functionality for Mortgage. 

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments, we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.

http://www.transunion.com/business

Contact	Dave Blumberg
	TransUnion
E-mail	david.blumberg@transunion.com
Telephone	312-972-6646

SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of PSV359 for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors (SFTs).

SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in an ongoing Phase 1/2a study in patients with advanced FAP-positive solid tumors. Published clinical imaging research has demonstrated FAP-targeted tracer uptake in SFTs, supporting the biological rationale for evaluating a FAP-directed therapy in this disease.¹ Early human imaging data for PSV359 support strong tumor uptake and fast renal clearance.

The FDA’s Fast Track program is intended to facilitate development and expedite the review of therapies for serious conditions with unmet medical needs.² Programs that receive Fast Track Designation may benefit from more frequent interactions with the FDA regarding the development program. A Fast Track-designated product may also qualify for rolling review, Accelerated Approval, or Priority Review if the applicable requirements for those programs are met.² FDA treats these as distinct expedited programs with separate qualifying criteria.

“FAP-α is a particularly compelling target because of its broad expression across solid tumors and within the tumor microenvironment, creating the potential for PSV359 to address a substantial patient population across multiple cancer types,” said Markus Puhlmann, Perspective’s Chief Medical Officer. “There are currently no approved therapies specifically targeting FAP-α, despite its association with aggressive cancers and tumor environments that can limit drug penetration and suppress immune activity. Imaging FAP-α expression before treatment allows us to pair patient selection with targeted alpha radiopharmaceutical therapy and pursue that broad opportunity with precision.”

“Fast Track designation for FAP-positive solitary fibrous tumors is an important step in advancing the broader PSV359 program and our strategy of engineering targeted radiopharmaceutical therapy based on the alpha-generating isotope ²¹²Pb to optimize the therapeutic window in oncology,” said Thijs Spoor, Perspective’s Chief Executive Officer. “We look forward to working with the FDA and the medical community to define an efficient development path for PSV359 in this rare and serious disease.”

About FAP

FAP is a cell-surface protein expressed predominantly by cancer-associated fibroblasts (CAFs) in the stroma, an important component of the tumor microenvironment (TME) in many epithelial cancers. FAP may also be expressed directly by certain cancer cells, including sarcomas and mesotheliomas.^3,4,5,6 Higher FAP-α expression has been found to be associated with poor prognosis in a number of solid tumors such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, stomach cancer, mesothelioma, head and neck cancer, esophageal cancer, and ovarian cancer.^{7,8,9,10,11,12} FAP-α expression is generally limited in healthy tissues.^5,6

About PSV359

PSV359 was designed to target and deliver ²¹²Pb to tumor sites expressing FAP-α, associated with multiple highly prevalent solid tumors, with patients in need of additional treatment options. The targeting moiety may also be radiolabeled with ²⁰³Pb or ⁶⁸Ga (known as PSV377) to detect FAP-α expression in individual patients. Preclinical imaging and therapy, as well as early human imaging results, have demonstrated that Perspective’s proprietary targeting ligand improves target engagement and uptake in tumors and reduces retention in healthy tissues, which may result in a desirable therapeutic index.

Perspective is conducting a multi-center, open-label, dose-finding and dose-expansion study (clinicaltrials.gov identifier NCT06710756) of [²¹²Pb]PSV359 in patients with advanced solid tumors that express FAP-α as determined by imaging with [²⁰³Pb]PSV359. The primary objective of the dose-finding phase of the study is to assess the safety and tolerability of various doses of [²¹²Pb]PSV359 in order to inform selection of the recommended Phase 2 dose for use in the expansion phase. Antitumor activity may be evaluated as an additional primary outcome in the expansion portion of the study.

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s proprietary technology, imaging techniques and product candidates, including PSV359, and related treatment opportunities; the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs, including the potential for PSV359 to address a substantial patient populations across multiple cancer types; the anticipated clinical benefits of the Company’s product candidates relative to existing therapies; the Company’s expectations regarding regulatory pathways for its product candidates; the expected benefits regarding the U.S. Food and Drug Administration’s (“FDA”) Fast Track Designation for PSV359, and PSV359’s potential eligibility for accelerated approval, priority review and rolling review; the Company’s expectations regarding its interactions with regulatory agencies, including the FDA, and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include (without limitation) that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; regulatory authorities may not grant or may delay approval for our product candidates; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; FDA’s designation for PSV359 may not provide the anticipated benefits and could be subject to withdrawal; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

---

¹ Hamacher R, Pabst KM, Cheung PF, et al. Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor. J Nucl Med. 2024;65(2):252-257. Published 2024 Feb 1. doi:10.2967/jnumed.123.266411
² Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics. https://www.fda.gov/media/86377/download?attachment. Accessed September 9, 2026.
³ Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87(18):7235-7239. doi:10.1073/pnas.87.18.7235
⁴ Dziadek S, Kraxner A, Cheng WY, et al. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies. Front Immunol. 2024;15:1352615. Published 2024 Mar 15. doi:10.3389/fimmu.2024.1352615
⁵ Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-805. doi:10.2967/jnumed.119.227967
⁶ Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783-803. doi:10.1007/s10555-020-09909-3
⁷ Cords L, Engler S, Haberecker M, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396-412.e5. doi:10.1016/j.ccell.2023.12.021
⁸ Coto-Llerena M, Ercan C, Kancherla V, et al. High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes. Front Oncol. 2020;10:979. Published 2020 Jul 8. doi:10.3389/fonc.2020.00979
⁹ Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736-1741. doi:10.1158/1078-0432.CCR-06-1746
¹⁰ Wang S, Zheng Y, Yang F, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6(1):249. Published 2021 Jul 5. doi:10.1038/s41392-021-00659-4
¹¹ Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154-158. doi:10.1097/MPA.0b013e31816618ce
¹² Ma C, Xi S, Sun, H, et al. Identifying the oncogenic roles of FAP in human cancers based on systematic analysis. Aging 2023;15(14):7056-7083. doi: 10.18632/aging.204892

#FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Rotork Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	07/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.5p ordinary
	Interests		Short positions
	Number	%		Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	15,542,057	1.90		11,211	0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	15,542,057	1.90		11,211	0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.5p ordinary	Equity swap	Increasing a long position	81	4.8860 GBP
0.5p ordinary	Equity swap	Increasing a long position	1,299	4.8860 GBP
0.5p ordinary	Equity swap	Increasing a long position	23	4.8860 GBP

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	08/10/2026
Contact name:	Graham Keene
Telephone number:	+44 20 7144 2259

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

METTAWA, Ill., Oct. 08, 2026 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will release its 2026 third quarter financial results on Thursday, October 29, 2026, before the market opens by way of an advisory release, notifying the public that the complete and full-text results will be available on the Company’s website. The results will also be available on the SEC’s website with the Form 8-K filing of the release.

The Company will hold a conference call at 10 a.m. CT / 11 a.m. ET, Thursday, October 29, 2026, hosted by David M. Foulkes, chairman and chief executive officer, Ryan M. Gwillim, executive vice president, chief financial officer, and chief strategy officer, Aine Denari, executive vice president, president Navico Group, and Brunswick chief technology officer, and Stephen Weiland, senior vice president, finance, and deputy CFO. A copy of the presentation to be used on this call will be available when the results are released as noted above.

The webcast can be accessed at Brunswick.com and here:  Webcast | Brunswick Corporation Q3 2026 Earnings Conference Call. A replay of the conference call will be available through 1 p.m. CT Thursday November 5, 2026, at the same link.

About Brunswick Corporation

Brunswick Corporation (NYSE: BC) is a global leader in marine recreation, delivering innovation that transforms experiences on the water and beyond. Its technology-driven solutions are informed by deep consumer insights and guided by the belief that “Next Never Rests™.” Brunswick is home to more than 60 industry-leading brands across marine propulsion (including Mercury Marine), parts and accessories (including Attwood), and marine electronics (including Simrad and Lowrance), as well as boat brands including Boston Whaler, Sea Ray, Bayliner, Lund, and Harris. Headquartered in Mettawa, Illinois, Brunswick has approximately 14,000 employees operating in 26 countries. Learn more at Brunswick.com.

Forward-Looking Statements

Certain statements in this news release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations, estimates, and projections about Brunswick’s business and by their nature address matters that are, to different degrees, uncertain. Words such as “may,” “could,” “should,” “will,” “expect,” “anticipate,” “project,” “position,” “intend,” “target,” “plan,” “seek,” “estimate,” “believe,” “predict,” “outlook,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties that may cause actual results to differ materially from expectations as of the date of this news release. These risks include, but are not limited to: the effect of adverse general economic conditions, including rising interest rates, and the amount of disposable income consumers have available for discretionary spending; changes to trade policy and tariffs, including retaliatory tariffs; fiscal and monetary policy changes; adverse capital market conditions; changes in currency exchange rates; competitive pricing pressures; higher energy and fuel costs; managing our manufacturing footprint and operations; loss of key customers; international business risks, geopolitical tensions or conflicts, sanctions, embargoes, or other regulations; actual or anticipated increases in costs, disruptions of supply, or defects in raw materials, parts, or components we purchase from third parties; supplier manufacturing constraints, increased demand for shipping carriers, and transportation disruptions; adverse weather conditions, climate change events and other catastrophic event risks; our ability to develop new and innovative products and services at a competitive price; absorbing fixed costs in production; our ability to meet demand in a rapidly changing environment; public health emergencies or pandemics; our ability to successfully implement our strategic plan and growth initiatives; attracting and retaining skilled labor, implementing succession plans for key leadership and executing organizational and leadership changes; our ability to integrate acquisitions and the risk for associated disruption to our business; the risk that restructuring or strategic divestitures will not provide business benefits; our ability to identify and complete targeted acquisitions; maintaining effective distribution; dealer and customer ability to access adequate financing; inventory reductions by dealers, retailers, or independent boat builders; requirements for us to repurchase inventory; risks related to the Freedom Boat Club franchise business model; outages, breaches, or other cybersecurity events regarding our technology systems, which have affected and could further affect manufacturing and business operations and could result in lost or stolen information and associated remediation costs; our ability to protect our brands and intellectual property; an impairment to the value of goodwill and other assets; product liability, warranty, and other claims risks; legal, environmental, and other regulatory compliance, including increased costs, fines, and reputational risks; risks associated with joint ventures that do not operate solely for our benefit; changes in income tax legislation or enforcement; managing our share repurchases; and risks associated with certain divisive shareholder activist actions.

Additional risk factors are included in the Company’s Annual Report on Form 10-K for 2025 and in subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date on which they are made, and Brunswick does not undertake any obligation to update them to reflect events or circumstances after the date of this news release.

CONTACT: Lee
Gordon —
Chief Communications Officer
M: (904) 860-8848 | O: (847) 735-4003

MONTREAL, Oct. 08, 2026 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce the assays of the previously announced 202-metre interval (see press release dated September 17 2026) at its Anatacau Main Project, located 20 km east of Rio Tinto’s Galaxy project, in the Eeyou Istchee James Bay region of Quebec.

This intercept is a significant discovery for Brunswick Exploration and will be the focus of future exploration work.

Highlights include:

• Results confirmed the mineralization of the Anais dyke observed in drill hole AN-25-15 with an intercept of 202.45 meters returning 1.31% Li2O from 274.25 to 476.70 meters.
• Higher grade core of 85 meters grading 1.73% Li2O represents a substantial jump in grade observed to date at Anais.
• The Anais dyke remains open in all directions and has significantly expanded following this drill hole.
• Drill hole AN-26-15 also returned two other major pegmatitic intervals: 1.41% Li2O over 21.5 meters and 1.28% Li2O over 9.2 meters. Both intercepts are separate from the Anais dyke and point to a much wider mineralized system at Anatacau.
• More results are pending.

Mr. Killian Charles, President and CEO of BRW, commented: “Anais is rapidly improving, not just in width, as the considerable length of the intercept highlights, but also in grade. These assay results are extremely encouraging and underscore the potential that exists at Anais. Importantly, we remain at the start of the discovery process. Anais is open in all directions. Over the course of the last twelve months, every drill hole that intercepted the main dyke has consistently grown it. We believe this trend will continue. Excitingly, drilling is still ongoing at Anatacau and I am looking forward to discussing future results with existing and prospective shareholders.”

Figure 1: Surface Map of the Anatacau Main Project and Drill Holes Completed

Figure 2: Cross Section A-A’ (see Figure 1 for Location)

Figure 3: Regional Map of the Anatacau Main and Anatacau West Projects

Discussion of Results

To date, a total of four holes totaling approximately 1,700 meters have been drilled in the Anais sector, with all assay results pending except for hole AN-26-15.

Hole AN-26-15 returned three major pegmatitic intervals: 1.28% Li2O over 9.2 meters, 1.41% Li2O over 21.50 meters, and 1.31% Li2O over 202.45 meters, confirming the Anais Main dyke to a vertical depth of 300 meters. The 202.45 meters intercept contained an 85.75 meter high-grade zone returning 1.73% Li2O. These pegmatite intervals contain between 10-30% spodumene crystals, and are generally coarse grained, pale colored and unaltered. Mica, predominantly muscovite, and other accessory mineral content is low. The combination of large spodumene crystals and low accessory mineral content should be well represented in future planned metallurgical studies. Preliminary review of the upper and lower contact of the intercept suggests that the Anais dyke changes from a sub vertical dip near surface to a shallower 45 degrees dip a depth. Further drilling will seek to confirm this change in orientation.

Table 1: Results from AN-26-25

Hole ID	From (m)	To (m)	Core length (m)	Li2O (%)
AN-26-15	170.8	180	9.2	1.28
	211.4	232.9	21.5	1.41
	274.25	476.7	202.45	1.31
	including
	298.4	384.15	85.75	1.73

*The true thickness of the Anais dyke is estimated to be approximately 75%
**Interval total can contain up to 25% country rocks

Table 2: Drill Hole Collars (UTM Nad83, Zone 18N)

Drill Holes	Azimuth	Dip	Length (m)	UTM X	UTM Y	Elevation (m)
AN-26-15	125	52	498	380198	5784693	198

Note

SEC Technical Report Summary for the James Bay Lithium Project prepared by SLR Consulting (Canada), Wave International Pty and WSP Canada for Arcadium Lithium Plc., dated August 31, 2023.

QAQC

All drill core samples were collected under the supervision of BRW employees and services contractor Explo-Logik, applying industry-standard QA/QC procedures to its drilling and prospecting programs. All sample preparation and analytical work were performed by Agat Laboratories. Samples were be prepared with methods 200075 and 200087 and dissolved in a sodium peroxide solution, prior to multielement analysis by ICP-OES and ICP-MS according to the Agat method 201378. All results passed the QA/QC screening at the laboratory, and all inserted standard, duplicates and blanks returned results within acceptable limits.

Qualified Person

The scientific and technical information contained in this press release has been reviewed and approved by Mr. Simon T. Hébert, VP Development. He is a Professional Geologist registered in Quebec and is a Qualified Person as defined by National Instrument 43-101.

About Brunswick Exploration

Brunswick Exploration is a Montreal-based mineral exploration company listed on the TSX-V under symbol BRW. The Company is focused on grassroots exploration for lithium in Canada, a critical metal necessary to global decarbonization and energy transition. The company is rapidly advancing the most extensive grassroots lithium property portfolio in Canada, Greenland and Saudi Arabia underpinned by its Mirage project, one of the largest undeveloped hard-rock lithium Inferred Mineral Resource Estimate in the Americas, with 52.2Mt grading 1.08% Li2O.

Investor Relations/information

Mr. Killian Charles, President and CEO (info@BRWexplo.com)

Contact number: 514 861 4441

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/c005fd65-6c6f-465b-bc30-71513584a3c6
https://www.globenewswire.com/NewsRoom/AttachmentNg/af2fce1d-9bca-48e7-bc95-c5a260ea4f4d
https://www.globenewswire.com/NewsRoom/AttachmentNg/4645b5ba-c73d-4b86-8acb-9d6d536f1702

Multi-Year Engine Exchange Program Extends from V2500, Replacing Traditional Shop Visits with Serviceable Engines Delivered Ahead of Scheduled Removals

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) — FTAI Aviation Ltd. (Nasdaq: FTAI; the “Company” or “FTAI”) today announced a multi-year Maintenance, Repair and Exchange (“MRE”) agreement with United Airlines (Nasdaq: UAL; “United”), one of the world’s largest CFM56-7B operators, under which FTAI is providing engine exchanges in lieu of traditional shop visits. The companies’ exchange relationship began with United’s V2500-powered fleet and has been extended to designated CFM56-7B engines with the program structured to grow over its term.

Under the MRE program, FTAI delivers a serviceable engine ahead of each of United’s scheduled removals and then purchases United’s unserviceable engine in exchange, sparing the airline the cost and downtime of a traditional shop visit. FTAI adds each acquired engine to its inventory as feedstock for its MRO network. The program started with an initial group of engines in 2026 and will continue to expand over its term as additional engines come due for removal, with FTAI and United jointly planning deliveries against the airline’s removal schedule.

“United is one of the most respected operators in our industry, and its decision to adopt FTAI’s engine exchange program is a meaningful endorsement,” said Joe Adams, Chairman and CEO of FTAI. “This agreement allows United to keep its aircraft flying and its maintenance costs predictable, while FTAI takes on the shop visit. We are honored to be selected by an operator of United’s caliber.”

“This is an important step forward in our maintenance program for our Boeing 737 NG aircraft,” said United Executive Vice President and Chief Financial Officer Mike Leskinen. “This growing relationship will help us improve utilization for this important part of our fleet as we fly more customers to more destinations.”

About FTAI

FTAI combines advanced turbine technology and asset ownership to power the world’s most essential markets. Additional information is available at https://www.ftaiaviation.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the expected benefits of the agreement, FTAI’s ability to provide engine exchanges in lieu of shop visits for the covered engines, the phasing of the program and the addition of engines to the program over its term, the anticipated reduction in maintenance costs and downtime for the covered engines, and the expected contribution of exchanged engines to FTAI’s inventory. These statements are based on management’s current expectations and beliefs and are subject to a number of trends and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, many of which are beyond the Company’s control. The Company can give no assurance that its expectations will be attained and such differences may be material. Accordingly, you should not place undue reliance on any forward-looking statements contained in this press release. For a discussion of some of the risks and important factors that could affect such forward-looking statements, see the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the Company’s website (www.ftaiaviation.com). In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results to differ from those contained in any forward-looking statements. Such forward-looking statements speak only as of the date of this press release. The Company expressly disclaims any obligation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or change in events, conditions, or circumstances on which any statement is based. This release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. Nothing on the Company’s website is included or incorporated by reference herein.

For further information, please contact:

FTAI:
Charlie Arestia
Investor Relations
FTAI Aviation Ltd.
(646) 276-4418
ir@ftaiaviation.com

Media:
Tim Lynch / Kelly Sullivan
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Boca Raton, FL, Oct. 08, 2026 (GLOBE NEWSWIRE) — Powell Max Limited (NASDAQ:PMAX) (“Powell Max” or the “Company”) congratulates Remington Firearms on its announcement that newly manufactured firearms from its new state-of-the-art facility in LaGrange, Georgia, are expected to begin reaching U.S. distribution and retail channels this fall.

The LaGrange facility represents a significant investment in Remington’s manufacturing platform, combining the heritage of one of America’s most recognized firearms brands with modern manufacturing technology, advanced production capabilities and a strong focus on quality, consistency and performance.

The initial rollout is expected to include two of Remington’s most established product platforms: Model 700 rifles and Model 870 shotguns. These products are expected to be available through a broad network of independent firearms dealers, hometown gun shops, regional outdoor retailers, farm and sporting-goods stores, and major outdoor retail destinations.

New production from LaGrange marks an important milestone in Remington’s manufacturing strategy, strengthening the company’s ability to support its core product lines and expand product availability across established U.S. distribution and retail channels.

With its new Georgia facility moving toward full-scale production, Remington is positioned to capitalize on the strength and recognition of its historic brand, support broader product availability and create a platform for future growth.

The Company acquired a 1.5% initial equity stake in Blackrod Holdings, LLC, which owns the exclusive rights to manufacture and sell Remington Firearms – see the Company’s Form 6-K filed on September 28, 2026.

About Powell Max Limited

Powell Max Limited is a financial communications services provider headquartered in Hong Kong. The Company maintains a U.S. subsidiary incorporated in Delaware, with corporate staff located in Boca Raton, Florida. The Company engages in the provision of financial communications services that support capital market compliance and transaction needs for corporate clients and their advisors in Hong Kong. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. The Company’s clients consist of domestic and international companies listed in Hong Kong, together with companies who are seeking to list in Hong Kong, as well as their advisors.

Forward-Looking Statements

Certain statements made in this communication are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of PMAX’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investors Contact:  

IR@PMAXltd.com

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce production results for the third quarter (“Q3”) of 2026 from its Kainantu Gold Mine in Papua New Guinea.

Q3 2026 Production Results

• Strong quarterly production of 49,776 ounces gold equivalent (“AuEq”)⁽¹⁾ or 46,063 oz gold, 1,948,951 lbs copper and 55,746 oz silver (Figure 1), representing the second-highest quarterly production to date. Quarterly sales of 41,587 oz gold, 1,912,770 lbs copper and 53,575 oz silver. Production is expected to be strongest in Q4, driven by a planned higher-grade stoping sequence and increased mining rates, supported by the continued ramp-up of the second and third mining fronts, which commenced stoping in April and September, respectively, and the completion of multiple key Stage 3 and 4 Expansion enabler projects that improve underground productivity (see “Stage 3 Expansion” below). The Company reiterates its 2026 production guidance of 190,000 to 225,000 oz AuEq (see January 26, 2026 press release).
• Significant production milestone achieved during the quarter – one million AuEq ounces produced since declaring commercial production in February 2018. This milestone highlights the exceptional growth achieved by translating significant exploration success into multiple phases of production expansion through strong operational and project execution.
• Record quarterly ore processed of 250,042 tonnes (Figure 2), an 82% increase from Q3 2025 and an 11% increase from Q2 2026, with a head grade of 6.6 grams per tonne (“g/t”) AuEq, or 6.1 g/t gold, 0.4% copper and 8.5 g/t silver.
• Strong metallurgical recoveries in Q3 of 94.1% for gold and 94.9% for copper (Figure 3), exceeding the updated definitive feasibility study (“Updated DFS”) recovery parameters of 92.6% and 94.2%, respectively (January 1, 2024 effective date), with gold recoveries exceeding the Updated DFS parameter for the 10th consecutive quarter. The new 1.2 million tonnes-per-annum (“tpa”) Stage 3 Expansion Process Plant has continued to perform well since commissioning was completed in December 2025, achieving record monthly throughput of 92,937 tonnes in September 2026 and the year’s second-highest daily throughput of 3,725 tonnes on September 19, 13% above the plant’s design capacity of 3,290 tonnes per day (“tpd”).
• Record quarterly mine development of 3,486 metres, a 41% increase from Q3 2025, including a new monthly development record of 1,220 metres achieved in July. Lateral development rates averaged 1,162 metres per month in Q3, 16% above the Stage 3 Expansion requirement of 1,000 metres per month, with July also exceeding the Stage 4 Expansion requirement of 1,200 metres per month. Further improvements in lateral development rates are expected following completion of commissioning of the Phase 4 Primary Ventilation Upgrade, scheduled for Q4 2026, and the planned arrival of an additional development jumbo in late Q4 to expand the development fleet. The Company is targeting development rates above Stage 4 Expansion requirements in 2027 to further increase operational flexibility.
• Record quarterly total material mined (ore plus waste) of 485,812 tonnes (a 37% increase from Q3 2025 and a 14% increase from Q2 2026), supported by the continued ramp-up of the second mining front and improved material handling following completion of the second material pass and the internal ramp earlier in the year. Recent completion of major haul road and river crossing upgrades, the upcoming completion of commissioning of the Phase 4 Primary Ventilation Upgrade and the ongoing expansion of the Load and Haul fleet are expected to drive further increases in mine physicals (see “Stage 3 Expansion” below).
• Record quarterly ore mined of 252,744 tonnes (a 66% increase from Q3 2025), with mining activity across 14 levels, including the 1010, 1030, 1070, 1090, 1130, 1325, 1345, 1365, 1385 and 1405 levels at Kora, and the 1030, 1050, 1070, 1090, 1110, 1185, 1365, 1385 and 1425 levels at Judd. Long hole stoping performed to design. First stope ore from the third mining front (Twin Incline) was delivered in September, with the operation expected to expand to four mining fronts in 2027.

Stage 3 Expansion – Major Progress on Key Surface and Underground Projects

• As at September 30, 2026, 98% of Stage 3 Expansion growth capital has either been spent or committed, with the expansion remaining on budget.
• During Q3, construction and commissioning activities continued across the key pastefill infrastructure projects:
  • Surface Tailings Filtration Plant – Filtration plant is now operational with production optimization work ongoing.
  • Surface Paste Binder Blending Area and Filter Cake Storage Facility – Structural, mechanical and piping works are complete, with remaining electrical and instrumentation installations progressing toward planned commissioning in early Q4 2026.
  • Underground Paste Plant and Reticulation – On the 1205 level, the silo hopper, feeder, paste and colloidal mixers have been installed. At the 1170 pump chamber, both paste pumps have been installed. All major equipment has now been installed. Remaining civil, structural, mechanical and electrical works are progressing well, together with paste reticulation installation across multiple levels, with commissioning targeted for Q4 2026.
• During the quarter, key Stage 3 Expansion underground infrastructure and operational excellence projects continued to advance, supporting the ongoing mine ramp-up, including:
  • Material Pass System – The second material pass, operational since June, has provided a significant boost to material handling capabilities in the Main Mine and Lower Kora, with dedicated ore and waste passes supporting efficient truck haulage to surface via the Twin Incline. Development of a third material pass is advancing towards targeted completion in Q4 2026, further improving material handling capacity to support the ongoing mine ramp-up.
  • Phase 4 Primary Ventilation Upgrade – Electrification was completed during Q3, with completion of commissioning targeted for the second half of October 2026. The upgrade will increase primary mine airflow capacity from approximately 350 m³/s to 600 m³/s, (expandable to ~700 m³/s), exceeding Stage 4 Expansion and life-of-mine ventilation requirements. This significant increase in primary ventilation capacity is expected to further reduce blast clearance times and enable highly productive one-way or dedicated traffic flow through the Twin Inclines, supporting increased underground material movement and mining rates. To conserve power, the variable speed drive fans will initially operate according to mine demand and ramp up as required.
  • Load, Haul and Development Fleet Expansion – Five new 60-tonne Volvo surface trucks commenced operating in late Q3, with the remaining three trucks expected to arrive in Q4 2026. This fleet will haul directly to the process plant from underground (via the Twin Incline), reducing material rehandling and haul road congestion, and increasing overall haulage capacity. Two replacement Sandvik 45-tonne underground trucks and an additional Sandvik LH621i loader are also expected in Q4 to replace higher hour underground trucks and further expand loader capacity. The LH621i adds to the four new Sandvik LH517i underground loaders brought into operation earlier in 2026, representing a net increase of three loaders following replacement of two high-hour units. An additional development jumbo is also scheduled to arrive in late Q4 to support higher planned lateral development rates in 2027.
• Major surface haul road and river crossing upgrades advanced during the quarter, with the Baupa and Kokomo bridges and Kasese river crossing now complete, tripling payload capacity from 20 tonnes to 60 tonnes. Remaining haul road upgrade works are nearly complete. Together, these improvements are expected to reduce haulage cycle times, support Stage 3 and Stage 4 Expansion throughput requirements and deliver operating cost efficiencies through economies of scale.

Note (1): Gold equivalent production for Q3 2026 is calculated based on: gold $4,308 per ounce; silver $63.89 per ounce; and copper $6.38 per pound. Gold equivalent grade for Q3 incorporates realized recoveries of 94.1% for Au, 94.9% for Cu and 81.3% for Ag.

David Medilek, K92 Chief Executive Officer and Director, stated, “Q3 marked another strong quarter for K92, with production of 49,776 ounces gold equivalent, our second-highest quarterly production result, and multiple quarterly operational records, including lateral development, ore mined, ore processed and total tonnes mined. During the quarter, we also surpassed one million ounces gold equivalent produced since commercial production was declared in February 2018, a significant milestone reflecting the growth achieved by translating significant exploration success into multiple phases of production expansion through strong operational and project execution.

I would like to thank our employees, contractors, local communities, partners and all stakeholders who have contributed to this achievement. In particular, I would like to acknowledge the continued support of Papua New Guinea’s Government, which has been a major factor in our growth and success. As I begin my tenure as CEO, I am proud to celebrate this milestone with our team and recognize John Lewins’ leadership in Kainantu’s growth and development. I look forward to continuing my close working relationship with John in his role as Non-Executive Chair. We will build on this foundation as we continue to execute the Stage 3 and 4 Expansions to deliver our next phase of growth.

Looking ahead, Q4 is expected to deliver a further step forward as the second and third mining fronts continue to ramp up and key infrastructure projects are completed. Commissioning of the Phase 4 Primary Ventilation Upgrade, completion of the remaining haul road ancillary upgrades and continued deployment of the new 60-tonne surface trucks are expected to increase material movement capacity and improve operating flexibility. Together with a planned higher-grade stoping sequence and the continued strong performance of the Stage 3 process plant, these improvements position us for our strongest production quarter of the year and reinforce our confidence in achieving full-year guidance.”

See Figure 1: Quarterly Production, Co-Product Cash Cost and Co-Product AISC Chart
See Figure 2: Quarterly Ore Processed, Development, and Mined Material Chart
See Figure 3: Gold and Copper Recoveries Chart

Table 1 – 2025 & 2026 Production Data

		Q3 2025		Q4 2025		2025		Q1 2026		Q2 2026		Q3 2026
Tonnes Processed	T	137,172		186,198		557,156		142,017		225,965		250,042
Feed Grade Au	g/t	10.7		7.4		9.7		10.2		6.2		6.1
Feed Grade Cu	%	0.47%		0.53%		0.51%		0.56%		0.39%		0.37%
Recovery (%) Au	%	95.0%		94.3%		94.7%		95.1%		93.8%		94.1%
Recovery (%) Cu	%	94.6%		93.9%		94.5%		94.0%		93.2%		94.9%
Metal in Conc & Doré Prod Au	oz	42,244		44,129		164,484		44,022		42,931		46,063
Metal in Conc Prod Cu	T	600		880		2,695		770		808		884
Metal in Conc Prod Ag	oz	34,831		47,427		159,309		38,845		50,109		55,746
Gold Equivalent Production	oz	44,323		47,178		174,134		46,743		46,093		49,776

Notes –	Gold equivalent for Q3 2026 is calculated based on: Gold $4,308 per ounce; silver $63.89 per ounce; and copper $6.38 per pound.
	Gold equivalent for Q2 2026 is calculated based on: gold $4,561 per ounce; silver $73.55 per ounce; and copper $6.03 per pound.
	Gold equivalent for Q1 2026 is calculated based on: gold $4,717 per ounce; silver $78.37 per ounce; and copper $5.77 per pound.
	Gold equivalent for Q4 2025 is calculated based on: gold $4,131 per ounce; silver $56.44 per ounce; and copper $5.11 per pound.
	Gold equivalent for Q3 2025 is calculated based on: gold $3,507 per ounce; silver $38.71 per ounce; and copper $4.49 per pound.

Qualified Person

K92 Mine Chief Geologist, Andrew Kohler, PGeo, a qualified person under the meaning of Canadian National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and is responsible for the technical content of this news release. Data verification by Mr. Kohler includes significant time onsite reviewing drill core, face sampling, underground workings, and discussing work programs and results with geology and mining personnel.

Technical Report

The Updated Definitive Feasibility Study and mineral resource estimate for the Kainantu Gold Mine Project in Papua New Guinea are presented in a technical report, titled, “Independent Technical Report, Kainantu Gold Mine, Updated Definitive Feasibility Study, Kainantu Project, Papua New Guinea” dated March 21, 2025, with an effective date of January 1, 2024.

About K92

K92 Mining Inc. is engaged in the production of gold, copper and silver at the Kainantu Gold Mine in the Eastern Highlands province of Papua New Guinea, as well as exploration and development of mineral deposits in the immediate vicinity of the mine. The Company declared commercial production from Kainantu in February 2018, is in a strong financial position, and is working to become a Tier 1 mid-tier producer through ongoing plant expansions. A maiden resource estimate on the Blue Lake copper-gold porphyry project was completed in August 2022. K92 is operated by a team of mining company professionals with extensive international mine-building and operational experience.

On Behalf of the Company,

David Medilek, Chief Executive Officer and Director

For further information, please contact Mick Sroba, Director Business Development and Investor Relations at +1-604-416-4445

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Such forward-looking statements include, without limitation: (i) the results of the Kainantu Mine Definitive Feasibility Study, including the Stage 3 Expansion, a new standalone 1.2 million tonnes-per-annum process plant and supporting infrastructure; (ii) statements regarding the expansion of the mine and development of any of the deposits; (iii) the Kainantu Stage 4 Expansion, operating two standalone process plants, larger surface infrastructure and mining throughputs; and (iv) the potential extended life of the Kainantu Mine.

All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as “expect”, “plan”, “anticipate”, “project”, “target”, “potential”, “schedule”, “forecast”, “budget”, “estimate”, “intend” or “believe” and similar expressions or their negative connotations, or that events or conditions “will”, “would”, “may”, “could”, “should” or “might” occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements are necessarily based on estimates and assumptions that are inherently subject to known and unknown risks, uncertainties and other factors, many of which are beyond our ability to control, that may cause our actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Such factors include, without limitation, Public Health Crises, including the epidemic or pandemic viruses; changes in the price of gold, silver, copper and other metals in the world markets; fluctuations in the price and availability of infrastructure and energy and other commodities; fluctuations in foreign currency exchange rates; volatility in price of our common shares; inherent risks associated with the mining industry, including problems related to weather and climate in remote areas in which certain of the Company’s operations are located; failure to achieve production, cost and other estimates; risks and uncertainties associated with exploration and development; uncertainties relating to estimates of mineral resources including uncertainty that mineral resources may never be converted into mineral reserves; the Company’s ability to carry on current and future operations, including development and exploration activities at the Arakompa, Kora, Judd and other projects; the timing, extent, duration and economic viability of such operations, including any mineral resources or reserves identified thereby; the accuracy and reliability of estimates, projections, forecasts, studies and assessments; the Company’s ability to meet or achieve estimates, projections and forecasts; the availability and cost of inputs; the availability and costs of achieving the Stage 3 Expansion or the Stage 4 Expansion; the ability of the Company to achieve the inputs the price and market for outputs, including gold, silver and copper; failures of information systems or information security threats; political, economic and other risks associated with the Company’s foreign operations; geopolitical events and other uncertainties, such as the conflicts in Ukraine, Russia, and the Middle East; compliance with various laws and regulatory requirements to which the Company is subject to, including taxation; the ability to obtain timely financing on reasonable terms when required; the current and future social, economic and political conditions, including relationship with the communities in Papua New Guinea and other jurisdictions it operates; other assumptions and factors generally associated with the mining industry; and the risks, uncertainties and other factors referred to in the Company’s Annual Information Form under the heading “Risk Factors”.

Estimates of mineral resources are also forward-looking statements because they constitute projections, based on certain estimates and assumptions, regarding the amount of minerals that may be encountered in the future and/or the anticipated economics of production. The estimation of mineral resources and mineral reserves is inherently uncertain and involves subjective judgments about many relevant factors. Mineral resources that are not mineral reserves do not have demonstrated economic viability. The accuracy of any such estimates is a function of the quantity and quality of available data, and of the assumptions made and judgments used in engineering and geological interpretation, Forward-looking statements are not a guarantee of future performance, and actual results and future events could materially differ from those anticipated in such statements. Although we have attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking statements, there may be other factors that cause actual results to differ materially from those that are anticipated, estimated, or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Figure 1: Quarterly Production, Co-Product Cash Cost and Co-Product AISC Chart

Figure 2: Quarterly Ore Processed, Development, and Mined Material Chart

Figure 3: Gold and Copper Recoveries Chart

Telephone: +1 (604) 416-4445
Facsimile: +1 (604) 608-9110
www.k92mining.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/865bd292-b148-40df-a423-4d7f8e7894ab

https://www.globenewswire.com/NewsRoom/AttachmentNg/e1f6a7bb-5e39-472f-8cd0-5e9fcba2c71c

https://www.globenewswire.com/NewsRoom/AttachmentNg/c73d5798-5d4d-4287-a632-86b787eed343

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Senior Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	07/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	10p ordinary
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	10,831,673	2.54
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	10,831,673	2.54

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
10p ordinary	Equity Swap	Increasing a long position	591	2.9750 GBP
10p ordinary	Equity Swap	Increasing a long position	842	2.9750 GBP
10p ordinary	Equity Swap	Increasing a long position	35	2.9750 GBP

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	08/10/2026
Contact name:	Graham Keene
Telephone number:	+44 20 7144 2259

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.